Calcium crystal deposition diseases: Lessons from histochemistry

Current Opinion in Rheumatology

Volumn 16, Issue 3, 2004, Pages 279-281

  Masuda, Ikuko ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

CPPD; Hypertrophic chondrocytes; Immunohistochemistry; Inorganic pyrophosphate

Indexed keywords

ALKALINE PHOSPHATASE; BLOOD CLOTTING FACTOR 8A; CALCIUM PYROPHOSPHATE; COLLAGEN TYPE 10; COLLAGENASE 3; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

APOPTOSIS; CALCIFICATION; CARTILAGE CELL; CRYSTALLIZATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MINERALIZATION; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

CALCINOSIS; CALCIUM; CARTILAGE, ARTICULAR; CHONDROCALCINOSIS; CHONDROCYTES; CRYSTALLIZATION; ENZYMES; EXTRACELLULAR MATRIX; HISTOCYTOCHEMISTRY; HUMANS; TRANSGLUTAMINASES;

EID: 1942500128     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200405000-00019     Document Type: Review

References (27)

1. Ryan LM, McCarty DJ: Calcium pyrophosphate crystal deposition disease. In Arthritis and Allied Conditions, edn 13. Edited by Koopman W. Baltimore: Williams and Wilkins; 1997;2103-2126.
2. Halverson PB, McCarty DJ: Basic calcium phosphate (apatite, octacalcium phosphate, tricalcium phosphate) crystal deposition diseases. In Arthritis and Allied Conditions, edn 13. Edited by Koopman W. Baltimore: Williams and Wilkins; 1997:2127-2146.
3. Derfus BA, Kurian JB, Butler JJ, et al.: The high prevalence of pathologic calcium crystals in preoperative knees. J Rheumatol 2002, 29:570-574. A high prevalence (60%) of BCP or CPPD crystals were found in synovial fluids from preoperative knees. Only 33% of these cases showed radiographic chondrocalcinosis.
4. Eerola I, Salminen H, Lammi P, et al.: Type X collegen, a natural component of mouse articular cartilage: association with growth, aging, and osteoarthritis. Arthritis Rheum 1998, 41:1287-1295.
5. Hashimoto S, Takahashi K, Ochs RL, et al.: Nitric oxide production and apoptosis in cells of meniscus during experimental osteoarthritis. Arthritis Rheum 1999, 42:2123-2131.
6. Ishikawa K, Masuda I, Ohira T, et al.: A histological study of calcium pyrophosphate dihydrate crystal deposition disease. J Bone Joint Surg Am 1989, 71:875-886.
7. Masuda I, Ishikawa K, Usuku G: A histologic and immunohistochemical study of calcium pyrophosphate dihydrate crystal deposition disease. Clin Orthop Rel Res 1991, 263:272-287.
8. Krane SM: Petulant cellular acts: destroying the ECM rather than creating it. J Clin Invest 2001, 107:31-32.
9. Gerstenfeld LC, Shapiro FD: Expression of bone-specific genes by hypertrophic chondrocytes: implication of the complex functions of the hypertrophic chondrocyte during endochondral bone development. J Cell Biochem 1996, 62:1-9.
10. Alini M, Carey D, Hirata S, et al.: Cellular and matrix changes before and at the time of calcification in the growth plate studied in vitro: arrest of type X collagen synthesis and net loss of collagen when calcification is initiated. J Bone Miner Res 1994, 9:1077-1087.
11. Nurminskaya M, Linsenmayer TF: Identification and characterization of up-regulated genes during chondrocyte hypertrophy. Dev Dyn 1996, 206:260-271.
12. Aeschlimann D, Wetterwald A, Fleisch H, et al.: Expression of tissue transglutaminase in skeletal tissues correlates with events of terminal differentiation in chondrocytes. J Cell Biol 1993, 120:1461-1470.
13. Aeschlimann D, Thomazy V: Protein cross-linking in assembly and remodeling of extracellular matrices: the role of transglutaminases. Connect Tissue Res 2000, 41:1-27.
14. Greenberg CS, Birckbichler PJ, Rice RH: Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J 1991, 5:3071-3078.
15. Aeschlimann D, Mosher D, Paulsson M: Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Semin Thromb Haemost 1996, 22:437-443.
16. Rosenthal AK, Gohr CM, Henry LA, et al.: Participation of transglutaminase in the activation of latent transforming growth factor beta1 in aging articular cartilage. Arthritis Rheum 2000, 43:1729-1733.
17. Rosenthal AK, Masuda I, Gohr CM, et al.: The transglutaminase, factor XIIIA, is present in articular chondrocytes. Osteoarthritis Cartilage 2001, 9:578-581.
18. Rosenthal AK, Derfus BA, Henry LA: Transglutaminase activity in aging articular chondrocytes and articular cartilage vesicles. Arthritis Rheum 1997, 40:966-970.
19. Johnson K, Hashimoto S, Lotz M, et al.: Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am J Pathol 2001, 159:149-163.
20. Johnson K, van Etten D, Nanda N, et al.: Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy. J Biol Chem 2003, 278:18824-18832. Distinct TG2-independent and TG2-dependent mechanisms promote Cbfa1 expression, articular chondrocyte hypertrophy, and calcification.
21. Ali SY, et al.: Ultrastructural studies of pyrophosphate crystal deposition in articular cartilage. Ann Rheum Dis 1983, 42(suppl):97-98.
22. Ryan LM, Wortmann RL, Karas B, et al.: Cartilage nucleoside triphosphate (NTP) pyrophosphohydrolase. I. Identification as an ecto-enzyme. Arthritis Rheum 1984, 27:404-409.
23. Ho AM, Johnson MD, Kingsley DM: Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000, 289:265-270.
24. Johnson K, Hashimoto S, Lotz M, et al.: Up-regulated expression of the phosphodiesterase nucleotide pyrophosphatase family member PC-1 is a marker and pathogenic factor for knee meniscal cartilage matrix calcification. Arthritis Rheum 2001, 44:1071-1081.
25. Yamakawa K, Iwasaki H, Masuda I, et al.: Cartilage intermediate layer protein expression in calcium pyrophosphate dihydrate crystal deposition disease. J Rheumatol 2002, 29:1746-1753.
26. Johnson K, Farley D, Hu SI, et al.: One of two chondrocyte-expressed isoforms of cartilage intermediate-layer protein functions as an insulin-like growth factor 1 antagonist. Arthritis Rheum 2003, 48:1302-1314. Increased expression of cartilage intermediate-layer protein-1, via N-terminal domain-mediated inhibitory effects of cartilage intermediate-layer protein-1 on chondrocyte insulinlike growth factor-1 responsiveness, could impair chondrocyte growth and matrix repair and indirectly promote PPi supersaturation in aging and OA cartilage.
27. Ohira T, Ishikawa K: Histochemical localization of calcium with potassium pyroantimonate in the articular tissues in calcium pyrophosphate dihydrate crystal deposition disease. Clin Orthop Rel Res 1991, 264:286-294.